<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.openbell.ai/</loc>
    <lastmod>2026-10-08T10:47:47.613Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://www.openbell.ai/support</loc>
    <lastmod>2026-10-08T10:47:47.613Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://www.openbell.ai/privacy</loc>
    <lastmod>2026-10-08T10:47:47.613Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.openbell.ai/terms</loc>
    <lastmod>2026-10-08T10:47:47.613Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.openbell.ai/feed.json</loc>
    <lastmod>2026-10-08T10:47:47.613Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/NVDA:1791456418111</loc>
    <lastmod>2026-10-08T10:46:58.111Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>&amp;#39;Nvidia-Backed IPO’s Cratering Demand Sends Warning on AI Funding&amp;#39; - Bloomberg</image:title>
      <image:caption>Recent IPOs backed by Nvidia are experiencing a significant decline in demand, raising concerns about the future of funding in the AI sector. This trend could indicate a broader market shift affecting investments in artificial intelligence technologies. The situation highlights potential challenges for companies looking to raise capital in the current economic climate.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/F:1791456408614</loc>
    <lastmod>2026-10-08T10:46:48.614Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/F/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Jim Farley Says Ford&amp;#39;s Next-Gen EVs Will Check Themselves for Assembly Defects: &amp;#39;The Vehicle Diagnoses Itself&amp;#39;</image:title>
      <image:caption>Ford Motor Co. CEO Jim Farley announced that the company&#39;s upcoming Universal EV Platform will enable vehicles to self-diagnose assembly defects during production, aiming to enhance quality control after experiencing 78 recalls this year. The system will allow vehicles to conduct internal checks shortly after receiving power, while still utilizing traditional inspection methods. Ford is set to launch its all-electric Fathom pickup, the first vehicle on this platform, with a starting MSRP of $28,350 and preorders beginning in early 2027.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/HELE:1791456367115</loc>
    <lastmod>2026-10-08T10:46:07.115Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/HELE/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Helen Of Troy Raises FY2027 GAAP EPS Guidance from $3.57-$4.18 to $3.63-$4.26 vs $3.77 Est</image:title>
      <image:caption>Helen Of Troy (NASDAQ: HELE) has raised its FY2027 GAAP EPS guidance from a range of $3.57-$4.18 to $3.63-$4.26, surpassing the analyst estimate of $3.77. This adjustment reflects a positive outlook for the company&#39;s earnings in the upcoming fiscal year.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/HELE:1791456337757</loc>
    <lastmod>2026-10-08T10:45:37.757Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/HELE/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Helen Of Troy Raises FY2027 Adj EPS Guidance from $3.25-$3.75 to $3.60-$4.15 vs $3.55 Est; Narrows FY2027 Sales Guidance from $1.759B-$1.831B to $1.768B-$1.822B vs $1.808B Est</image:title>
      <image:caption>Helen Of Troy (NASDAQ: HELE) has raised its FY2027 adjusted EPS guidance from a range of $3.25-$3.75 to $3.60-$4.15, surpassing the analyst estimate of $3.55. Additionally, the company has narrowed its FY2027 sales outlook from $1.759 billion-$1.831 billion to $1.768 billion-$1.822 billion, compared to an estimate of $1.808 billion.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/LLY:1791456236737</loc>
    <lastmod>2026-10-08T10:43:56.737Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/LLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440</image:title>
      <image:caption>Cantor Fitzgerald analyst Carter Gould has maintained an Overweight rating on Eli Lilly (NYSE: LLY) and raised the price target from $1410 to $1440. This adjustment reflects a positive outlook on the company&#39;s performance.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/GILD:1791456172400</loc>
    <lastmod>2026-10-08T10:42:52.400Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GILD/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target</image:title>
      <image:caption>Cantor Fitzgerald analyst Carter Gould has reiterated an &#39;Overweight&#39; rating on Gilead Sciences (NASDAQ: GILD) and maintained a price target of $155 for the stock. This endorsement suggests confidence in Gilead&#39;s future performance in the market.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/HNRG:1791456166625</loc>
    <lastmod>2026-10-08T10:42:46.625Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/HNRG/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Hallador Energy Enters Six-Year, $700M Capacity And Energy Agreements With A MISO Zone 6 Utility Covering Deliveries From The Merom Generating Station From June 1, 2029, Through May 31, 2035; Revenue Jumps from $46/MWh For 2026 To $75/MWh For 2031-2035</image:title>
      <image:caption>Hallador Energy has entered into six-year capacity and energy agreements worth $700 million with a MISO Zone 6 utility, covering deliveries from the Merom Generating Station from June 1, 2029, to May 31, 2035. The capacity agreement, priced at the highest level to date, will generate approximately $271 million in capacity revenue, while the energy agreement is expected to yield around $422 million. These agreements increase Hallador&#39;s total forward sales book to $3 billion and secure approximately 95% of Merom&#39;s accredited capacity through 2035. Additionally, the company is advancing its Turtle Creek natural gas project, which would expand its generating capacity by over 40%.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/NVA:1791455876432</loc>
    <lastmod>2026-10-08T10:37:56.432Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Nova Minerals Announces That Equipment For Its Planned Antimony Processing And Refinery Operation Arrived At Port Mackenzie On October 6</image:title>
      <image:caption>Nova Minerals has announced the arrival of key equipment for its planned antimony processing and refinery operation at Port Mackenzie on October 6, enabling construction to begin pending final permits. This milestone supports the company&#39;s initiative to create a vertically integrated U.S. domestic antimony supply chain in Alaska, backed by a $43.4 million award from the U.S. Department of War. Additionally, the 2026 field program at the Estelle Critical Minerals and Gold Project has been completed, with initial assay results expected soon.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/ABBV:1791455809599</loc>
    <lastmod>2026-10-08T10:36:49.599Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ABBV/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290</image:title>
      <image:caption>Cantor Fitzgerald analyst Carter Gould has maintained an Overweight rating on AbbVie (NYSE: ABBV) and raised the price target from $285 to $290. This adjustment reflects a positive outlook on the company&#39;s performance.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/SPTX:1791455719180</loc>
    <lastmod>2026-10-08T10:35:19.180Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/SPTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>HC Wainwright &amp;amp; Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target</image:title>
      <image:caption>HC Wainwright &amp; Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Seaport Therapeutics (NASDAQ: SPTX) and maintained a price target of $50 for the stock.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/RDY:1791455631435</loc>
    <lastmod>2026-10-08T10:33:51.435Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/RDY/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Dr Reddy&amp;#39;s Says FDA Completed Pre-Approval Inspection At The FTO-11 Manufacturing Facility In Pydibhimavaram</image:title>
      <image:caption>Dr Reddy&#39;s Laboratories announced that the FDA has completed a pre-approval inspection at its FTO-11 manufacturing facility located in Pydibhimavaram. This inspection is a crucial step in the regulatory process for the company&#39;s products. The outcome of the inspection may impact the company&#39;s ability to launch new pharmaceutical products in the market.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/AVGO:1791455559519</loc>
    <lastmod>2026-10-08T10:32:39.519Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Konskie--Poland---January-11--2024-Broad.jpg?width=250&amp;height=187</image:loc>
      <image:title>Broadcom Eyes Over $50 Billion to Fund OpenAI’s Custom AI Chips as Oracle Also Pursues Major Chip Financing: Report</image:title>
      <image:caption>Broadcom Inc. is seeking over $50 billion in financing to develop custom AI chips for OpenAI, with discussions involving Apollo Global Management and Blackstone. The funding aims to support significant chip capacity for AI data centers, with expectations for the deal to close by year-end. Separately, Oracle is also pursuing substantial financing for a large-scale chip purchase, negotiating with Apollo and Goldman Sachs.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/CRBU:1791455355481</loc>
    <lastmod>2026-10-08T10:29:15.481Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/CRBU/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>HC Wainwright &amp;amp; Co. Downgrades Caribou Biosciences to Neutral</image:title>
      <image:caption>HC Wainwright &amp; Co. analyst Robert Burns has downgraded Caribou Biosciences (NASDAQ: CRBU) from a &#39;Buy&#39; rating to &#39;Neutral&#39;. This change reflects a shift in the firm&#39;s outlook on the company&#39;s performance.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/NOMD:1791455049593</loc>
    <lastmod>2026-10-08T10:24:09.593Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NOMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>BTIG Reiterates Buy on Nomad Foods, Maintains $15 Price Target</image:title>
      <image:caption>BTIG analyst Peter Saleh has reiterated a Buy rating on Nomad Foods (NYSE: NOMD) and maintained a price target of $15. This endorsement reflects confidence in the company&#39;s performance and market position.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/PLTR:1791454986456</loc>
    <lastmod>2026-10-08T10:23:06.456Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/PLTR/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Goldman Sachs Upgrades Palantir Technologies to Buy, Announces $230 Price Target</image:title>
      <image:caption>Goldman Sachs analyst Gabriela Borges has upgraded Palantir Technologies (NASDAQ: PLTR) from a Neutral rating to a Buy rating. Additionally, the firm has set a price target of $230 for the stock.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/LEVI:1791454969006</loc>
    <lastmod>2026-10-08T10:22:49.006Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/LEVI/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Needham Reiterates Buy on Levi Strauss, Maintains $28 Price Target</image:title>
      <image:caption>Needham analyst Tom Nikic has reiterated a Buy rating on Levi Strauss (NYSE: LEVI) and maintained a price target of $28 for the stock. This endorsement reflects confidence in the company&#39;s performance and market position.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/APLD:1791454866452</loc>
    <lastmod>2026-10-08T10:21:06.452Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Applied-Digital-Corporation.jpg?width=250&amp;height=187</image:loc>
      <image:title>Applied Digital CEO Says AI Demand Is Near Maximum</image:title>
      <image:caption>Applied Digital Corporation (NASDAQ: APLD) reported a first-quarter adjusted revenue of $300.39 million, exceeding analyst estimates of $132.16 million, driven by its high-performance computing hosting business which generated $262.6 million. The company has approximately $36 billion in contracted revenue and expects to bring over 600 MW online in the next 12 months. CEO Wes Cummins noted that AI data center demand remains high, with nearly all capacity for 2027 already under contract. APLD shares rose 4.03% to $24.77 in premarket trading.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/CATX:1791454654405</loc>
    <lastmod>2026-10-08T10:17:34.405Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/CATX/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors</image:title>
      <image:caption>Perspective Therapeutics has received FDA Fast Track Designation for its investigational therapy PSV359, aimed at treating adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors (SFTs). PSV359 is currently being evaluated in a Phase 1/2a study and has shown promising early human imaging data indicating strong tumor uptake. The Fast Track program will facilitate the development and review process, potentially allowing for more frequent interactions with the FDA and eligibility for expedited approval pathways.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/VYLR:1791454395733</loc>
    <lastmod>2026-10-08T10:13:15.733Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/VYLR/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Goldman Sachs Initiates Coverage On Vylor with Buy Rating, Announces Price Target of $87</image:title>
      <image:caption>Goldman Sachs analyst Duffy Fischer has initiated coverage on Vylor (NYSE: VYLR) with a Buy rating. The firm has set a price target of $87 for the stock.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/GNRC:1791454369026</loc>
    <lastmod>2026-10-08T10:12:49.026Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GNRC/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Keybanc Upgrades Generac Holdings to Overweight, Announces $280 Price Target</image:title>
      <image:caption>Keybanc analyst Jeffrey D. Hammond has upgraded Generac Holdings (NYSE: GNRC) from Sector Weight to Overweight, setting a price target of $280 for the stock. This upgrade indicates a positive outlook for the company&#39;s performance in the market.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/NESR:1791454280840</loc>
    <lastmod>2026-10-08T10:11:20.840Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NESR/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>National Energy Services Reunited Unit NESR Environmental And Decarbonization Applications Partners With Aramco To Execute The 2027 Lithium Demonstration Project; Implies Up To Five-Year Contract Value Of ~$200M</image:title>
      <image:caption>National Energy Services Reunited (NESR) has partnered with Aramco to execute a lithium demonstration project aimed at producing 2,000 tons per annum of battery-grade lithium carbonate, with commissioning expected by late 2027. The project has an implied contract value of approximately $200 million over five years. This collaboration leverages Aramco&#39;s subsurface expertise and NESR&#39;s LiThara™ technology for efficient lithium extraction, addressing the growing demand for battery materials in the energy transition.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/RCKT:1791454167792</loc>
    <lastmod>2026-10-08T10:09:27.792Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/RCKT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4</image:title>
      <image:caption>Goldman Sachs has upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from a &#39;Sell&#39; rating to &#39;Neutral.&#39; The price target for the stock has been increased from $3 to $4, as stated by analyst Richard Law.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/IMOS:1791454060437</loc>
    <lastmod>2026-10-08T10:07:40.437Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/IMOS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>ChipMOS Technologies Reports Q3 Sales Of $263.8M, Up 36.7% YoY</image:title>
      <image:caption>ChipMOS Technologies Inc. reported third quarter 2026 revenue of $263.8 million, marking a 36.7% increase year-over-year and a 13.8% rise from the previous quarter. The growth is attributed to strong AI-related demand amid ongoing memory supply constraints. Additionally, September 2026 revenue was $87.7 million, reflecting a 0.2% increase from August 2026 and a 33.8% increase from September 2025.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/IMOS:1791454049843</loc>
    <lastmod>2026-10-08T10:07:29.843Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/IMOS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>ChipMOS TECHNOLOGIES Sees Prelim Q3 Sales $263.800M</image:title>
      <image:caption>ChipMOS TECHNOLOGIES (NASDAQ: IMOS) has reported preliminary sales of $263.800 million for the third quarter. This figure indicates the company&#39;s performance in the semiconductor industry during this period.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/CRUS:1791453907833</loc>
    <lastmod>2026-10-08T10:05:07.833Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Cloud-Computing-Digital-Information-Data.jpg?width=250&amp;height=187</image:loc>
      <image:title>Top 3 Tech Stocks That Could Lead To Your Biggest Gains This Quarter</image:title>
      <image:caption>Cirrus Logic Inc (NASDAQ: CRUS) announced the acquisition of INVENTVM on October 6, aiming to enhance its engineering capacity and market opportunities. The company&#39;s stock has fallen approximately 8% over the past five days, closing at $112.68 with an RSI of 29.3. Itron Inc (NASDAQ: ITRI) is set to announce its third-quarter results on October 27, with shares down 11% in the last month, closing at $85.58 and an RSI of 27.4. Fair Isaac Corp (NYSE: FICO) saw its stock drop 27% over the past month, closing at $681.77, following a price target reduction by Barclays, with an RSI of 29.8.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/SPCX:1791453898373</loc>
    <lastmod>2026-10-08T10:04:58.373Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Anthropic-Ai-Research-Company-Logo-Seen-.jpg?width=250&amp;height=187</image:loc>
      <image:title>Anthropic IPO Could Be 2026’s ‘Most Ridiculous’ Offering as Analyst Values AI Firm at Just $150 Billion: ‘Unprecedented Test of Investor Gullibility’</image:title>
      <image:caption>Anthropic is preparing for a potential IPO in 2026, with an estimated valuation of $150 billion, significantly lower than the projected $2 trillion market capitalization. The company reported revenue of $4.6 billion in 2025 but faced an operating loss of $8.06 billion and a net loss of approximately $42 billion. Analysts have raised concerns about its valuation, suggesting it would require extraordinary revenue growth to justify the high market cap, with estimates indicating the need for around $725 billion in annual revenue by 2036.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/DTI:1791453884678</loc>
    <lastmod>2026-10-08T10:04:44.678Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/DTI/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Drilling Tools International To Acquire Tool Rental Company Saltire For ~$80M In Cash And 17.4M DTI Shares</image:title>
      <image:caption>Drilling Tools International (DTI) has announced its acquisition of Saltire Energy Limited for approximately $80 million in cash and 17.4 million shares of DTI common stock, with the transaction expected to close in the first quarter of 2027. Saltire, a provider of rental drilling tools, is projected to generate run rate 2026 revenue of about $50.4 million and Adjusted EBITDA of approximately $22.5 million, reflecting a 45% margin. The acquisition is anticipated to enhance DTI&#39;s international presence, increasing its Eastern Hemisphere revenue contribution from 18% to 40% post-close.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/HUT:1791453851490</loc>
    <lastmod>2026-10-08T10:04:11.490Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/HUT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Roth Capital Reinstates Buy on Hut 8, Announces $108 Price Target</image:title>
      <image:caption>Roth Capital analyst Bryan Baratian has reinstated a Buy rating on Hut 8 (NASDAQ: HUT) and set a price target of $108 for the stock. This announcement indicates a positive outlook for Hut 8&#39;s performance in the market.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/PEP:1791453831524</loc>
    <lastmod>2026-10-08T10:03:51.524Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/PEP/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>PepsiCo Lowers FY2026 Adj EPS Guidance from $8.55-$8.71 to $8.34-$8.43 vs $8.55 Est; Narrows FY2026 Sales Guidance from $97.682B-$99.561B to $99.561B vs $98.879B Est</image:title>
      <image:caption>PepsiCo (NASDAQ: PEP) has revised its fiscal year 2026 adjusted earnings per share (EPS) guidance, lowering it from a range of $8.55-$8.71 to $8.34-$8.43, compared to an analyst estimate of $8.55. Additionally, the company has narrowed its sales outlook for FY2026 from a range of $97.682 billion-$99.561 billion to $99.561 billion, which is below the analyst estimate of $98.879 billion.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/ANGO:1791453778386</loc>
    <lastmod>2026-10-08T10:02:58.386Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ANGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>AngioDynamics Q1 Adj. EPS $(0.04) Beats $(0.11) Estimate, Sales $80.915M Beat $80.500M Estimate</image:title>
      <image:caption>AngioDynamics (NASDAQ: ANGO) reported a Q1 adjusted EPS of $(0.04), surpassing the analyst estimate of $(0.11) by 63.64%. This reflects a 60% increase in losses compared to $(0.10) per share from the same period last year. The company&#39;s sales reached $80.915 million, exceeding the $80.500 million estimate by 0.52% and marking a 6.87% increase from $75.711 million in the previous year.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/ITUB:1791453742468</loc>
    <lastmod>2026-10-08T10:02:22.468Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ITUB/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>HSBC Downgrades Itau Unibanco Holding to Hold, Announces $9.1 Price Target</image:title>
      <image:caption>HSBC analyst Carlos Gomez-Lopez has downgraded Itau Unibanco Holding (NYSE: ITUB) from a &#39;Buy&#39; rating to &#39;Hold&#39;. Alongside this downgrade, HSBC has set a price target of $9.1 for the stock.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/PEP:1791453620955</loc>
    <lastmod>2026-10-08T10:00:20.955Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/PEP/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>PepsiCo Q3 Adj. EPS $2.34 Beats $2.29 Estimate, Sales $25.274B Beat $24.962B Estimate</image:title>
      <image:caption>PepsiCo reported Q3 earnings of $2.34 per share, surpassing the analyst estimate of $2.29 by 1.74% and reflecting a 2.18% increase from the previous year&#39;s $2.29 per share. The company&#39;s quarterly sales reached $25.274 billion, exceeding the expected $24.962 billion by 1.25%, and marking a 5.59% increase from last year&#39;s $23.937 billion.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/SPCX:1791453560225</loc>
    <lastmod>2026-10-08T09:59:20.225Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Starlink.jpg?width=250&amp;height=187</image:loc>
      <image:title>Elon Musk’s SpaceX Gets Green Light from Trump&amp;#39;s FCC for 15,000 Starlink Satellites: Here’s What Comes Next</image:title>
      <image:caption>SpaceX has received approval from the Federal Communications Commission (FCC) to deploy 15,000 Non-Geostationary Orbit satellites for its Starlink direct-to-device constellation, enhancing its mobile connectivity services. The FCC&#39;s order allows SpaceX to operate without needing leasing agreements with ground-based service providers. Following this news, Goldman Sachs raised SpaceX&#39;s stock price target to $230, while Morgan Stanley set a target of $300, indicating strong investor interest despite a slight decline in premarket trading, with shares at $167.30.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/STZ:1791453520429</loc>
    <lastmod>2026-10-08T09:58:40.429Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/STZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>HSBC Downgrades Constellation Brands to Hold, Lowers Price Target to $135</image:title>
      <image:caption>HSBC analyst Sorabh Daga has downgraded Constellation Brands (NYSE: STZ) from a Buy rating to Hold. Additionally, the price target for the company&#39;s stock has been reduced from $192 to $135.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/ELMT:1791453228729</loc>
    <lastmod>2026-10-08T09:53:48.729Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ELMT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Needham Maintains Buy on The Elmet Group, Raises Price Target to $28</image:title>
      <image:caption>Needham analyst James Ricchiuti has maintained a Buy rating on The Elmet Group (NASDAQ: ELMT) and increased the price target from $25 to $28.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/AVGO:1791453123422</loc>
    <lastmod>2026-10-08T09:52:03.422Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/AVGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>&amp;#39;Oracle, Broadcom and SpaceX Seek Blockbuster Debt Deals To Pay for AI Chips&amp;#39;- WSJ Exclusive</image:title>
      <image:caption>Oracle, Broadcom, and SpaceX are pursuing significant debt deals to finance their investments in AI chip technology. These companies are looking to secure large amounts of capital to enhance their capabilities in the rapidly growing AI sector. The move reflects the increasing demand for advanced computing power driven by AI applications.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/P:1791453108777</loc>
    <lastmod>2026-10-08T09:51:48.777Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/P/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Needham Maintains Buy on Everpure, Raises Price Target to $185</image:title>
      <image:caption>Needham analyst Matthew Calitri has maintained a Buy rating on Everpure (NYSE: P) and increased the price target from $150 to $185. This adjustment reflects a positive outlook for the company&#39;s performance.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/LEVI:1791452874428</loc>
    <lastmod>2026-10-08T09:47:54.428Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/LEVI/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>BTIG Reiterates Buy on Levi Strauss, Maintains $27 Price Target</image:title>
      <image:caption>BTIG analyst Robert Drbul has reiterated a Buy rating on Levi Strauss (NYSE: LEVI) and maintained a price target of $27 for the stock. This endorsement suggests confidence in the company&#39;s performance and potential growth.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/VSTM:1791452743991</loc>
    <lastmod>2026-10-08T09:45:43.991Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/VSTM/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>BTIG Reiterates Buy on Verastem, Maintains $18 Price Target</image:title>
      <image:caption>BTIG analyst Jeet Mukherjee has reiterated a Buy rating on Verastem (NASDAQ: VSTM) and has maintained a price target of $18 for the stock. This endorsement suggests confidence in the company&#39;s future performance.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/GOOGL:1791452529754</loc>
    <lastmod>2026-10-08T09:42:09.754Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GOOGL/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Needham Reiterates Buy on Alphabet, Maintains $450 Price Target</image:title>
      <image:caption>Needham analyst Laura Martin has reiterated a Buy rating on Alphabet (NASDAQ: GOOGL) and has maintained a price target of $450 for the stock. This endorsement suggests confidence in Alphabet&#39;s market performance.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/SSNLF:1791452430993</loc>
    <lastmod>2026-10-08T09:40:30.993Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/USDC-USD-Coin-stablecoin-cryptocurrency-.jpg?width=250&amp;height=187</image:loc>
      <image:title>Samsung Brings USDC to Galaxy Wallet Users in US With Coinbase-Backed Launch</image:title>
      <image:caption>Samsung Electronics will introduce stablecoin wallet functionality for Galaxy users in the U.S. in the last week of October, supporting USDC, the second-largest stablecoin. Users can send USDC to compatible international wallets without transfer fees and to bank accounts in over 60 countries. Coinbase will custody the USDC held in Samsung Wallet through Coinbase Prime Vault. This announcement follows Samsung&#39;s raised third-quarter guidance, driven by AI-driven demand for memory chips, with detailed results expected on October 29.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/REZI:1791451783991</loc>
    <lastmod>2026-10-08T09:29:43.991Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Apple-logo-is-seen-at-the-Apple-Wangfuji.jpg?width=250&amp;height=187</image:loc>
      <image:title>Apple&amp;#39;s Smart Home Ambitions Hammer REZI, ARLO and ALLE Stocks: Here&amp;#39;s What&amp;#39;s Happening</image:title>
      <image:caption>Shares of smart home and security companies, including Resideo Technologies Inc. (REZI), Arlo Technologies Inc. (ARLO), and Allegion PLC (ALLE), fell sharply following reports that Apple Inc. is developing connected home devices in partnership with LG Electronics. REZI&#39;s stock dropped 7.19% to $17.56, ARLO fell 6.64% to $11.95, and ALLE decreased 4.70% to $147.91. In contrast, Apple shares rose 0.91% to close at $336.67, while Amazon and Alphabet saw slight gains amid the competitive landscape shift.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/RGP:1791451487577</loc>
    <lastmod>2026-10-08T09:24:47.577Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/RGP/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Conference call: Resources Connection Sees Q2 Sales $95.000M-$100.000M vs $107.010M Est</image:title>
      <image:caption>Resources Connection (NASDAQ: RGP) has projected Q2 sales between $95 million and $100 million, falling short of the analyst estimate of $107.01 million. This forecast indicates a potential revenue shortfall for the company in the upcoming quarter.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/ENTG:1791451365567</loc>
    <lastmod>2026-10-08T09:22:45.567Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ENTG/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Stifel Initiates Coverage On Entegris with Buy Rating, Announces Price Target of $200</image:title>
      <image:caption>Stifel analyst Brian Chin has initiated coverage on Entegris (NASDAQ: ENTG) with a Buy rating. He has set a price target of $200 for the company&#39;s stock.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/XOM:1791449686594</loc>
    <lastmod>2026-10-08T08:54:46.594Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Offshore-oil-and-gas-wellhead-remote-pla.jpg?width=250&amp;height=187</image:loc>
      <image:title>Trump EPA Moves To Roll Back Biden-Era Methane Rules, Says Changes Could Save Oil and Gas Producers $45 Billion</image:title>
      <image:caption>The Trump administration&#39;s EPA plans to roll back Biden-era methane regulations, targeting requirements for marginal wells and large-leak detection, which could save oil and gas producers an estimated $45 billion annually. The proposal includes creating separate standards for marginal well sites and rescinding the Super Emitter Program, which identifies major methane leaks. This move is part of a broader deregulatory effort by the Trump administration, aiming to alleviate compliance costs for major U.S. oil and gas companies such as Exxon Mobil, Chevron, and ConocoPhillips.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/APLD:1791448325356</loc>
    <lastmod>2026-10-08T08:32:05.356Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/The-Real-Villains-No-Longer-Hide.jpg?width=250&amp;height=187</image:loc>
      <image:title>Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket</image:title>
      <image:caption>Applied Digital Corp (NASDAQ: APLD) shares increased by 3.9% to $24.73 in pre-market trading following the release of its first-quarter financial results. The company reported adjusted revenue of $300.39 million, significantly surpassing analyst estimates of $132.16 million, and an adjusted loss of one cent per share, better than the expected loss of 30 cents per share.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/BHVN:1791447146516</loc>
    <lastmod>2026-10-08T08:12:26.516Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BHVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Biohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves&amp;#39; Disease</image:title>
      <image:caption>Biohaven has licensed its MoDE pan IgG degraders, including BHV-1300, to Ono for exclusive development and commercialization in Japan, South Korea, Taiwan, and ASEAN countries. The agreement includes up to $100 million in near-term payments, with $80 million upfront and an additional $20 million contingent on a milestone achievement. BHV-1300 is currently in Phase 3 development for Graves&#39; disease, showing promising results in earlier studies. Biohaven retains rights outside the licensed territories, including in the US, Europe, and China.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/GOOG:1791445828954</loc>
    <lastmod>2026-10-08T07:50:28.954Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Googles-Logo-On-The-Office-Building-In-C.jpg?width=250&amp;height=187</image:loc>
      <image:title>Google&amp;#39;s $15 Billion Finland AI Push Hits Roadblock as Regulators Order Halt at 2 Data Centers Pending Environmental Reviews</image:title>
      <image:caption>Alphabet Inc. (NASDAQ: GOOGL) has been ordered by Finland&#39;s Licensing and Supervision Agency to halt construction at two planned data centers in Muhos and Kajaani due to pending environmental impact reviews. This suspension affects various construction activities and must be implemented by October 23. The halt comes shortly after Google announced a €13 billion (approximately $15 billion) investment to enhance AI infrastructure in Finland, which includes commitments to clean energy and local partnerships.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/MDCX:1791444532015</loc>
    <lastmod>2026-10-08T07:28:52.015Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.benzinga.com/files/images/story/2026/10/08/Businessman-Examining-A-Declining-Stock-.jpg?width=250&amp;height=187</image:loc>
      <image:title>Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here&amp;#39;s Why</image:title>
      <image:caption>Medicus Pharma Ltd (NASDAQ: MDCX) shares dropped 24.22% to $0.12 in after-hours trading following the announcement of a 50-to-1 consolidation of its common shares, effective October 12. The consolidation aims to increase the share price and help the company meet Nasdaq&#39;s minimum bid price requirements. Medicus Pharma has a market capitalization of approximately $10.07 million and has seen its shares decline by 93.49% over the past year, trading between a 52-week high of $2.78 and a low of $0.14.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.openbell.ai/news/CME:1791444293060</loc>
    <lastmod>2026-10-08T07:24:53.060Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/CME/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>CME Group Q3 International Average Daily Volume Up 22% YoY To 9M Contracts On Energy, Agricultural, Equity Index Growth; Global Up 16% YoY To 29.4M</image:title>
      <image:caption>openbell Financial News</image:caption>
    </image:image>
  </url>
</urlset>